Treatment.Com International Inc. (TRUE.CN)
CAD 0.41
(-1.22%)
CAD 0.41
(-1.22%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.72 Million CAD | -0.62% |
| 2022 | -3.69 Million CAD | 73.27% |
| 2021 | -13.84 Million CAD | -375.93% |
| 2020 | -2.9 Million CAD | 3.19% |
| 2019 | -3 Million CAD | -4186.31% |
| 2018 | -70.08 Thousand CAD | 27.39% |
| 2017 | -96.51 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.71 Million CAD | -193.08% |
| 2024 Q1 | -926.64 Thousand CAD | 58.2% |
| 2023 Q2 | -288.07 Thousand CAD | 20.67% |
| 2023 Q4 | -2.21 Million CAD | -165.09% |
| 2023 Q3 | -836.18 Thousand CAD | -190.27% |
| 2023 FY | -3.72 Million CAD | -0.62% |
| 2023 Q1 | -363.1 Thousand CAD | 58.72% |
| 2022 Q4 | -879.68 Thousand CAD | -138.19% |
| 2022 Q3 | -369.31 Thousand CAD | 38.85% |
| 2022 Q2 | -603.95 Thousand CAD | 68.04% |
| 2022 FY | -3.69 Million CAD | 73.27% |
| 2022 Q1 | -1.88 Million CAD | 68.03% |
| 2021 Q4 | -5.9 Million CAD | -27.53% |
| 2021 FY | -13.84 Million CAD | -375.93% |
| 2021 Q3 | -4.63 Million CAD | -106.54% |
| 2021 Q2 | -2.24 Million CAD | -108.49% |
| 2021 Q1 | -1.07 Million CAD | 15.62% |
| 2020 Q4 | -1.27 Million CAD | -101.1% |
| 2020 FY | -2.9 Million CAD | 3.19% |
| 2020 Q3 | -634.21 Thousand CAD | 15.73% |
| 2020 Q2 | -752.61 Thousand CAD | -205.88% |
| 2020 Q1 | -246.04 Thousand CAD | 91.25% |
| 2019 Q4 | -2.81 Million CAD | -6638.47% |
| 2019 FY | -3 Million CAD | -4186.31% |
| 2019 Q3 | -41.71 Thousand CAD | 0.0% |
| 2018 FY | -70.08 Thousand CAD | 27.39% |
| 2017 FY | -96.51 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AI/ML Innovations Inc. | -3.28 Million CAD | -13.319% |
| Diagnamed Holdings Corp. | -1.27 Million CAD | -191.281% |
| Pangenomic Health Inc. | -2.97 Million CAD | -25.21% |
| nDatalyze Corp. | -155.6 Thousand CAD | -2292.261% |
| Unidoc Health Corp. | -2.25 Million CAD | -64.719% |